本公司已向联交所申请自2026年1月12日(星期一)上午九时正(香港时间)起于联交所恢复股份买卖。 LFG投资控股(03938)及要约人Fortune Origin International Capital(Holdings)Limited联合公布，于2025年 12月19日，卖方力高金融与要约人(作为买方)订立购股协议，卖方已有条件同意出售，而要约人已有条 件同意收购销售股份(即2.99亿股股份，相当于购股协议日期已发行股份总数的约61.43%及卖方在本公 司的全部持股)，总现金代价为1.797亿港元(相当于每股销售股份0.60港元)。 鉴于作为部分应付代价的1.2亿港元将以现金支付及作为要约人应付卖方代价余下结余的5969.53万港元 将透过发行承兑票据支付。 紧随完成后，要约人将于合共2.99亿股股份(相当于已发行股份总数约61.43%)中拥有权益。 根据收购守则规则26.1，于完成后，要约人将须就全部已发行股份(其及要约人一致行动人士已拥有及/ 或同意将予收购者除外)提出强制性无条件现金要约。每股要约股份现金0.60港元较2025年12月19日收 市价每股1.48港元折让约59.46%。 要约人从事 ...

Group 1 - The core transaction involves the acquisition of shares from A&B, Li Huaguo, and Yongjiayuan by CN BASE and the offeror, with total consideration amounting to 2,731.63 million HKD [1][2] - The agreement with A&B involves the purchase of shares equivalent to approximately 18.60% of the company's issued share capital for 14.32 million HKD, at a price of 0.50 HKD per share [1] - The agreement with Li Huaguo involves the purchase of shares equivalent to approximately 9.09% of the company's issued share capital for 7 million HKD, also at a price of 0.50 HKD per share [1] - The agreement with Yongjiayuan involves the purchase of shares equivalent to approximately 7.78% of the company's issued share capital for 5.9938 million HKD, at the same price of 0.50 HKD per share [2] Group 2 - Following the completion of these transactions, the offeror and its concert parties will collectively hold approximately 35.48% of the company's issued share capital, with the offeror holding 28.64 million shares and CN BASE holding 25.98 million shares [2] - The offeror is required to make a mandatory conditional cash offer for all issued shares at a price of 0.50 HKD per share, which represents a discount of approximately 65.75% compared to the last closing price of 1.460 HKD per share [2] - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on November 27, 2025 [2]

Core Viewpoint - The announcement details a conditional sale agreement between Anselme Limited (the offeror) and Li Jingyang (the seller) for the acquisition of 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share, which is a discount of about 68.10% compared to the market price on the announcement date [1][2]. Group 1 - The offeror will acquire 138.7 million shares, representing approximately 27.71% of the total issued share capital of Huakang Biomedical [1]. - Prior to the completion of the transaction, the offeror directly and beneficially owns 121 million shares, which is about 24.13% of the total issued share capital [1]. - Following the completion of the transaction, the offeror, Dr. Zhou, and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1]. Group 2 - The offeror is wholly owned by Dr. Zhou Xun Yong, who is also the sole director of the offeror [2]. - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [2].